有机锡2-(3-吡啶甲基硫代)苯甲酸酯与2-吡啶硫代乙酸酯的合成、结构与抗真菌活性

通过二乙基氧化锡、二丁基氧化锡以及三苯基氧化锡与2-(3-吡啶甲基硫代)苯甲酸和2-吡啶硫代乙酸的反应,3个四核有机锡羧酸酯以及2个单核三苯基锡羧酸酯被合成。它们的结构通过X-射线单晶衍射结构分析得到确证。生物活性测试表明,四核二丁基锡2-吡啶硫代乙酸酯以及单核三苯基锡2-(3-吡啶甲基硫代)苯甲酸酯对西瓜炭疽病菌、花生褐斑以及苹果轮纹菌等具有高的抑制活性。     

有机锡4-(4-吡啶基甲基硫代)苯甲酸酯的合成、结构与生物活性研究(英文)

通过4-(4-吡啶基甲基硫代)苯甲酸与三苯基氧化锡以及三环己基氢氧化锡反应,合成了三苯基锡4-(4-吡啶基甲基硫代)苯甲酸酯(1)及三环己基锡4-(4-吡啶基甲基硫代)苯甲酸酯(2)。它们的结构通过红外,核磁以及X-射线单晶衍射分析得到确证。化合物1表现为一维链状结构,而化合物2通过分子间的O-H…O和O-H…N氢键形成二维网状结构。生物活性测试表明,这2个化合物具有较高的抗肿瘤活性。     

2-{5-[(1H-1,2,4-三唑-1-基)甲基]-4-苯基-4H-1,2,4-三唑-3-硫基}-1-芳基乙酮类化合物的合成、表征及生物活性测试

通过α-卤代芳基乙酮和5-[(1H-1,2,4-三唑-1-基)甲基]-4-苯基-2H-1,2,4-三唑-3(4H)-硫酮反应, 合成了11个新的2-{5-[(1H-1,2,4-三唑-1-基)甲基]-4-苯基-4H-1,2,4-三唑-3-硫基}-1-芳基乙酮类化合物. 其结构经元素分析, IR, ¹H NMR等确证, 并用X射线单晶衍射测定了化合物6f的晶体结构. 生物活性测试结果表明, 部分化合物具有一定的杀菌活性.     

S-[(1,2,4-三唑-1-基)芳基(或烷基)甲羰]甲基二硫代磷酸酯衍生物的研究

探讨了S-[(1,2,4-三唑-1-基)芳基(或烷基)甲羰]甲基二硫代磷酸酯衍生物的合成方法,合成了12种含三唑有机磷新化合物,通过红外光谱分析,确定该类化合物P=S振动的吸收频率范围为640～680cm^-1,核磁共振氢谱证明,与磷原子相联的基团旋转部分受阻,生物初筛结果表明,部分化合物具有杀菌、除草及植物生长调节活性。     

(Z)-1-[2-(三苯基锡基)乙烯基]-1-茚满醇及其酯和卤代物的合成与表征

在氮气保护下,1-乙炔茚满醇与三苯基氢化锡进行游离基加成反应,获得加成物(Z)-1-[2-(三苯基锡基)乙烯基]-1-茚满醇(1);将加成物(1)与苯酐反应,得到新型邻苯二甲酸单酯有机锡衍生物(2);衍生物(2)分别与二丁基氧化锡和三苯基氧化锡进行脱水反应,分别获得两个新型邻苯二甲酸酯的有机锡衍生物(3)和(4).将加成物(1)与卤素反应后,与锡原子直接相连的苯基被取代,得到一卤代和二卤代物(5～10).通过元素分析、¹HNMR和IR等手段对化合物1～10进行了结构表征,确定了该类邻苯二甲酸单酯和邻苯二甲酸酯的有机锡衍生物的结构.并测定了加成物(1)和一溴代物(6)的晶体结构,在加成物(1)中,由于分子内存在较弱的O→Sn[0.2778(8)nm]配位作用,锡原子呈扭曲三角双锥构型.在一溴代物(6)分子中,存在分子内O→Sn[0.2364(2)nm]配位键,锡原子呈扭曲的三角双锥构型.该系列化合物分子内的O→Sn配位能力和Lewis酸性强弱的顺序为:二卤化物>一卤化物>加成物;氯代物>溴代物>碘代物>加成物.     

含肟醚的新型三唑并嘧啶衍生物的合成及除草活性研究

2-巯基-5,7-二甲基-1,2,4-三唑并[1,5-a]嘧啶(6)与氯乙醛或氯丙酮反应生成5,7-二甲基-1,2,4-三唑并[1,5-a]嘧啶-2-硫丙酮(硫乙醛) (7). 中间体7与O-烷基(芳基)羟胺(5)反应得到目标化合物1-(5,7-二甲基-1,2,4三唑[1,5-a]嘧啶-2-硫)乙醛-O-烷基肟醚(9), 2-(5,7-二甲基-1,2,4三唑[1,5-a]嘧啶-2-硫)丙酮O-烷基肟醚(10). 初步生物活性测试结果表明部分化合物具有较好的除草活性.     

有机锡4-(4-吡啶基甲基硫代)苯甲酸酯的合成、结构与生物活性研究

通过4-（4-吡啶基甲基硫代）苯甲酸与三苯基氧化锡以及三环己基氢氧化锡反应,合成了三苯基锡4-（4-吡啶基甲基硫代）苯甲酸酯（1）及三环己基锡4-（4-吡啶基甲基硫代）苯甲酸酯（2）。它们的结构通过红外,核磁以及X-射线单晶衍射分析得到确证。化合物1表现为一维链状结构,而化合物2通过分子间的O-H…O和O-H…N氢键形成二维网状结构。生物活性测试表明,这2个化合物具有较高的抗肿瘤活性。     

含吡唑1,2,4-三唑噻二嗪衍生物的合成及抑菌活性

1-苯基-3-甲基-5-氯-4-吡唑甲醛与4-氨基-5-取代苯基-1,2,4-三唑-3-硫酮缩合生成4-(1-苯基-3-甲基-5-氯吡唑次甲亚胺基)-5-(取代苯基)-2H-1,2,4-三唑-3(4H)-硫酮,再烷基加成化为新型含吡唑基5,6-2H-1,2,4-三唑[3,4-b][1,3,4]噻二嗪衍生物。 化合物结构经¹H NMR、IR以及元素分析确认。 初步生物活性测试结果表明,在100 mg/L浓度下,化合物8a(3-(2-甲基苯基)-6-(5-氯-2-甲基-4-苯基吡唑)-7-(4-硝基苯基)-5H-1,2,4-三唑[3,4-b][1,3,4]噻二嗪)对黄瓜炭疽病的抑制率达90%。     

新型1,2,4-三唑三氮烯衍生物的合成及其生物活性

以对氨基苯甲酸为原料,经多步反应合成了16个未见文献报道的1,2,4-三唑三氮烯衍生物.利用~1H NMR~,(13)C NMR和HRMS对标题化合的结构进行了表征.衍生物的细胞毒活性测试结果表明,2-[4-(3,3-二甲基三氮烯-1-基)苯基]-3-氨基-4-S-(4-氯基苄基)-1,2,4-三唑(6g)、2-[4-(3,3-二甲基三氮烯-1-基)苯基]-3-氨基-4-S-(2,4-二氯基苄基)-1,2,4-三唑(6h)、2-[4-(3,3-甲基苯甲基三氮烯-1-基)苯基]-3-氨基-4-S-苄基-1,2,4-三唑(6i)、2-[4-(3,3-甲基苯甲基三氮烯-1-基)苯基]-3-氨基-4-S-(4-甲基苄基)-1,2,4-三唑(6j)、2-[4-(3,3-甲基苯甲基三氮烯-1-基)苯基]-3-氨基-4-S-(4-甲氧基苄基)-1,2,4-三唑(6l)、2-[4-(3,3-甲基苯甲基三氮烯-1-基)苯基]-3-氨基-4-S-(2,4-二氯基苄基)-1,2,4-三唑(6p)对膀胱癌细胞具有较好的抑制作用,其IC50值分别为23.883,5.512,8.731,8.077,5.590和12.195μmol/L,化合物6h,6i,6j,6l对前列腺癌细胞具有较好的抑制作用,其IC50值分别为13.690,21.908,10.772和4.827μmol/L.     

2-[1-(1,2,4-三唑)甲基]-3-乙酰基-2,5-二取代芳基-1,3,4-噁二唑啉类化合物的合成

在冰醋酸存在下, 4-取代苯乙酮和溴素容易进行溴代反应, 得到α-溴-4-取代苯乙酮; 将其和1,2,4-三唑在丙酮中反应, 得到α-(1,2,4-三唑-1-基)-4-取代苯乙酮2; 在冰醋酸催化下, 2和4-取代苯甲酰肼1进行缩合, 得到相应酰腙衍生物3; 化合物3在乙酸酐的作用下环化生成一系列2-[1-(1,2,4-三唑)甲基]-3-乙酰基-2,5-二取代芳基-1,3,4-噁二唑啉4. 化合物4的结构经IR, 1H NMR, MS, 元素分析和单晶衍射确证.     

Optically active antifungal azoles. XI. An alternative synthetic route for 1

New routes for the synthesis of the optically active antifungal triazoles 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1b) and the 3-14-(1H-1,2,3-triazol-1-yl)phenyl]-2-imidazolidinone analog (1a) that possess an imidazolidine nucleus were established. The key synthetic intermediates, (2R,3R)-3-(2,2-diethoxvethyl)amino-2-(2,4-difluorophenyl)-1-(1H1,2,4-triazol-1-yl)-2-butanol (8) and (2R,3R)-2-(2,4-difiuorophenyl)-3-(2-h ydroxyethyl)amino-1-(1H-1,2,4-triazol-1-yl)-2-butanol (14), were prepared by the ring-opening reaction of the oxirane (2) with the corresponding 2-substituted ethylamines. The acetal (8) was converted to the imidazolidinones (1a, b) by condensation with the carbamates (10a, b) followed by treatment with hydrochloric acid and subsequent catalytic hydrogenation. The candidate selected for the clinical trials, 1b (TAK-456), was alternatively prepared from the hydroxyethylamino intermediate (14) via two reaction steps: condensation with the carbamate (10b) to the urea (15) and subsequent cyclization to the imidazolidinones. This newly developed synthetic route could be applied to a large scale preparation of 1b.     

Synthesis of nitrogen-containing heterocycles. 3. Formation and structure of new 1,2,4-triazole derivatives

Treatment of N(3)-[(2-cyano-2-ethoxycarbonyl)vinyl]amino-N(4),N(4)-dimethylaminomethylenehydrazones of aromatic carbonyl compounds with hot acetic acid resulted in the formation of symmetrical gem-bis-(3-dimethylamino-1,2,4-triazol-1-yl)methanes, (3-dimethylamino-1,2,4-triazol-1-yl)arylmethyl acetates, and (3-dimethylamino-1,2,4-triazol-1-yl)alkenes of a gem-diaryl type depending upon whether the carbonyl compound was aldehyde or ketone.     

Synthesis of New Thiazolo[3,2-b][1,2,4]triazole Derivatives and Preliminary Evaluation of Their Biological Activity

Russian Journal of General Chemistry - Heterocyclization of 3-[(1H-1,2,4-triazol-3-yl)thio]pentane-2,4-dione afforded 1-(6-methylthiazolo[3,2-b][1,2,4]-triazol-5-yl)ethan-1-one, the reactions of...     

Synthesis and Crystal Structure of 5-[（1H-1,2,4-Triazol-1- yl）methyl]-4-（2,3-dimethoxybenzylideneamino）-2- 2H-1,2,4-triazole-3（4H）-thione Monohydrate

1 INTRODUCTION Heterocyclic compounds bearing the 1,2,4-tri- azole moiety have attracted considerable attention over the past few decades since they exhibit some fungicidal activities against Puccinia recondite and applications in the field of root-growth regu- lation[1~3]. Meanwhile, 4-amino-5-mercapto-1,2, 4-triazole moiety has great versatility in fusing tovarious ring systems and possesses a broad spec- trum of biological activities[4, 5]. In our con- tinuous work directed towards the…     

Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-soluble prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone

1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1: TAK-456) was selected as a candidate for clinical trials, but since its water-solubility was insufficient for an injectable formulation, the quaternary triazolium salts 2 were designed as water-soluble prodrugs. Among the prodrugs prepared, 4-acetoxymethyl-1-[(2R,3R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-1-terazolyl)phenyl]-1-imidazolidinyl]butyl]-1H-1,2,4-triazolium chloride (2a: TAK-457) was selected as an injectable candidate for clinical trials based on the results of evaluations on solubility, stability, hemolytic effect and in vivo antifungal activities.     

Synthesis,anti-inflammatory and analgesic activity of 2-[4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid derivatives

The title compounds 3a–l have been synthesized by the reaction of thiocarbohydrazide with substituted phenoxy acetic acid to obtained substituted 1,2,4-triazoles (1). Compound 1 was treated with various substituted aromatic aldehydes which results in 4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-2H-1,2,4-triazol-3(4H)-thiones (2a–g), further 2a–g is converted to 2-[4-(substituted benzylideneamino)-5-(substituted phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3a–l) derivatives by the reaction with chloroacetic acid. All the newly synthesized compounds were evaluated for in vivo anti-inflammatory and analgesic activities. Among the series 2-[4-(2,4-dichlorobenzylideneamino)-5-(phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3d), 2-[4-(4-dichlorobenzylideneamino)-5-(phenoxymethyl)-4H-1,2,4-triazol-3-yl thio] acetic acid (3e), 2-[4-(2,4-dichlorobenzylideneamino)-5-[(2,4-dichlorophenoxy)methyl]-4H-1,2,4-triazol-3-yl thio] acetic acid (3j) and 2-[5-[(2,4-dichlorophenoxy)methyl)]-4-(4-chlorobenzylideneamino)-4H-1,2,4-triazol-3-yl thio] acetic acid (3k) showed significant anti-inflammatory activity with P < 0.001 (63.4%, 62.0%, 64.1% and 62.5% edema inhibition, respectively), as compared to the standard drug diclofenac (67.0%) after third hour respectively and also compounds 3j, 3k exhibited significant analgesic activity with P < 0.001 (55.9% and 54.9% protection, respectively) and less ulcerogenic activity as compared with standard drug aspirin (57.8%).     

Optically active antifungal azoles. X. Synthesis and antifungal activity of N

New optically active antifungal azoles, N-14-(azolyl)phenyl]- and N-14-(azolylmethyl)phenyl]-N'-[(IR,2R)-2(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(IH-1,2,4-triazol-1-yl)propyllazolones (1, 2, 3), were prepared in a stereocontrolled manner. Compounds 1-3 showed strong antifungal activity against Candida albicans in vitro. Among them, the imidazolidinones 3 showed a broad antifungal spectrum in vitro as well as potent in vivo activity against candidiasis and aspergillosis in mice. The imidazolidinones (3i, j, k) having 1H-1,2,3-triazol-1-yl, 2H-2-tetrazolyl and IH-1-tetrazolyl moieties were found to exert strong protective effect against aspergillosis.     

Synthesis and selected transformations of 1-(5-methyl-1-aryl-1H-1,2,3-triazol-4-yl)ethanones and 1-[4-(4-R-5-methyl-1H-1,2,3-triazol-1-yl)phenyl]ethanones

By cycloaddition of arylazides to acetylacetone are obtained derivatives of 1,2,3-triazole. In the reaction of 1-[5-methyl-1-(R-phenyl)-1H-1,2,3-triazol-4-yl] ethanones (IIa–IIe) and 1-[4-(4-R-5-methyl-1H-1,2,3-triazol-1-yl)phenyl] ethanones (VIIa-VIIe) with isatin are obtained 2-[1-(R-phenyl)-5-methyl-1H-1,2,3-triazol-4-yl]-4-quinolinecarboxylic acids (IIIa–IIIe) and 2-[4-(4-R-5-methyl-1H-1,2,3-triazol-1-yl)phenyl] -4-quinolinecarboxylic acids (IXa, IXb), respectively. We found that 1-[5-methyl-1-(R-phenyl)-1H-1,2,3-triazol-4-yl] ethanones (IIa–IIe) readily transform into [5-methyl-1-(R-phenyl)-1H-1,2,3-triazol-4-yl] acetic acids (IVa–IVc) by the method of Wilgerodt-Kindler. The (5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)acetic acid reacts with 5-phenyl-4-amino-4H-1,2,4-triazol-3-thiol affording 6-[(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl) methyl]-3-phenyl[1,2,4] triazolo[3,4-b] [1,3,4] thiadiazole (VI). Original Russian Text ? N.T. Pokhodylo, R.D. Savka, V.S. Matiichuk, N.D. Obushak, 2009, published in Zhurnal Obshchei Khimii, 2009, vol. 79, no. 2, pp. 320–325.     

3-（5-H/CH3-苯并咪唑-2-亚甲硫基）-5-取代-[1,2,4]三唑-4-胺衍生物的合成、结构和生物活性

利用3-巯基-4-氨基-5-取代-1,2,4-三唑和2-氯甲基-5-取代-苯并咪唑在氢氧化钠溶液中反应,得到17个3-(5-H/CH3-苯并咪唑-2-亚甲硫基)-5-取代-[1,2,4]三唑-4-胺衍生物.所有目标化合物经元素分析、红外光谱、核磁共振氢谱确定结构;采用溶液法得到化合物3f与Co2+形成的配合物,通过X射线单晶衍射确定结构.初步的生物活性测试结果表明,所合成的化合物对小麦芽鞘和绿豆发芽有着较好的生长调节作用;化合物3d,3i对金黄色葡萄球菌具有一定的抑制作用.     

A novel trinuclear titanium(IV) complex with a C3 axis along Ti1–Ti2–Ti3 containing 3-[(1H-1,2,4-triazol-1-yl)methyl]-BINOLate ligands: synthesis,structure, and reactivity

A new modified BINOL, (S)-3-[(1H-1,2,4-triazol-1-yl)methyl]-1,1′-binaphthol, was prepared. In the presence of titanium tetraisopropoxide, this ligand showed moderate catalytic properties for the asymmetric addition of diethylzinc to aldehydes. By treating rac-3-[(1H-1,2,4-triazol-1-yl)methyl]-1,1′-binaphthol with excess titanium tetraisopropoxide, a novel trinuclear titanium(IV) complex was obtained. A C₃ axis along Ti1–Ti2–Ti3 is present in the molecule.